Ozempic, a diabetes drug, shows promise for liver disease. Research indicates it can reverse non-alcoholic steatohepatitis. A ...

Once hailed primarily as a diabetes drug and later catapulted into stardom for its weight-loss benefits, Ozempic (semaglutide ...

A new study published in the New England Journal Of Medicine claimed that it can tackle non-alcoholic steatohepatitis or NASH ...

The U.S. Food and Drug Administration said Tuesday it will expand its use of unannounced inspections at foreign manufacturing ...

A test commonly used to confirm a condition linked to high blood pressure is often inaccurate, causing doctors to skip ...

Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...

GLP-1 receptor agonists remain blockbuster drugs for weight management for people with overweight or obesity. Increasingly, ...

For patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, semaglutide is associated with improved liver histologic outcomes.

The FDA has accepted for review the New Drug Application for a 25mg oral formulation of semaglutide for chronic weight management.

Madrigal Pharmaceuticals has a first mover advantage in the huge MASH market due to the approval of Rezdiffra. Read whether I ...